Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Negative Metastatic Breast Cancer × Breast × Clear all
NCT01948843 2016-04-14

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

Polaris Group

Phase 1 Completed
15 enrolled
Breast

HER2 Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡